Skip to main content

TEPEZZA (Amgen Australia Pty Ltd)

Product name
TEPEZZA
Date registered
Evaluation commenced
Decision date
Approval time
151 (255 working days)
Active ingredients
teprotumumab
Registration type
NCE/ NBE
Indication

TEPEZZA is indicated for the treatment of moderate to severe Thyroid Eye Disease (TED) (see section 5.1 Pharmacodynamic properties – Clinical trials).

Registration process

Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available

Help us improve this page